Paul Chaplin Steps Down as CEO of Bavarian Nordic

Core Viewpoint - Bavarian Nordic A/S announces the resignation of CEO Paul Chaplin for personal reasons, with a transition plan in place for the remainder of 2026 [1][3] Company Leadership Transition - Paul Chaplin has been with Bavarian Nordic since 1999 and became CEO in 2014, significantly contributing to the development of smallpox and mpox vaccines [2] - The Board of Directors has initiated the search for a new CEO while Chaplin will remain in his role until a successor is found [1][3] Company Growth and Achievements - Under Chaplin's leadership, Bavarian Nordic transformed from a small research-based company to a large vaccine manufacturer with strong commercial operations [2] - The company has successfully expanded its portfolio through strategic acquisitions and has established itself as a preferred supplier of vaccines to governments [4]